aluates Reports

$ 0.0

Automative

Mesalamine (Lialda) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Published Date: December 2024

Report Code: QYRE-Auto-6V6135

Global Mesalamine Lialda Market Insights and Forecast to 2028

BUY CHAPTERS

Mesalamine (Lialda) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-6V6135

Report

December 2024

Pages:114

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Dr. Falk Pharma

Ferring

Ethypharm Pharmaceutical

Shanghai Pharmaceutical

Tillotts Pharma

Holy Stone Healthcare

GIULIANI

Zeria

Lupin Ltd

Heilongjiang Tianhong Pharmaceutical

Hengcheng Pharmaceutical

KWAI FA Pharmaceutical Group

Mesalamine (Lialda) - Market Size

The global market for Mesalamine (Lialda) was estimated to be worth US$ 156.5 million in 2023 and is forecast to a readjusted size of US$ 228 million by 2030 with a CAGR of 5.6% during the forecast period 2024-2030

Mesalamine (Lialda) - Market

An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease 2. It is considered to be the active moiety of sulphasalazine. (From Martindale, The Extra Pharmacopoeia, 30th ed) Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent.

North American market for Mesalamine (Lialda) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Mesalamine (Lialda) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Europe market for Mesalamine (Lialda) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global key companies of Mesalamine (Lialda) include Dr.Falk Pharma, Ferring, Ethypharm Pharmaceutical, Shanghai Pharmaceutical, Tillotts Pharma, Holy Stone Healthcare, Giuliani, Zeria and Lupin, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Mesalamine (Lialda), focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Mesalamine (Lialda) by region & country, by Type, and by Application.

The Mesalamine (Lialda) market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mesalamine (Lialda).

Market Segmentation

Scope of Mesalamine (Lialda) - Market Report

Report Metric	Details
Report Name	Mesalamine (Lialda) - Market
Forecasted market size in 2030	US$ 228 million
CAGR	5.6%
Forecasted years	2024 - 2030
Segment by Type:	Enemas Tablets Suppositories Other
Segment by Application	Colitis Crohn's Disease Proctitis Diarrheal Irritable Bowel Syndrome Diverticulitis Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Dr.Falk Pharma, Ferring, Ethypharm Pharmaceutical, Shanghai Pharmaceutical, Tillotts Pharma, Holy Stone Healthcare, Giuliani, Zeria, Lupin, Heilongjiang Tianhong Pharmaceutical, HENGCHENG PHARMACEUTICAL, KWAI FA Pharmaceutical Group
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Mesalamine (Lialda) manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Mesalamine (Lialda) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Mesalamine (Lialda) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Mesalamine (Lialda) - Market size in 2030?

Ans: The Mesalamine (Lialda) - Market size in 2030 will be US$ 228 million.

Who are the main players in the Mesalamine (Lialda) - Market report?

Ans: The main players in the Mesalamine (Lialda) - Market are Dr.Falk Pharma, Ferring, Ethypharm Pharmaceutical, Shanghai Pharmaceutical, Tillotts Pharma, Holy Stone Healthcare, Giuliani, Zeria, Lupin, Heilongjiang Tianhong Pharmaceutical, HENGCHENG PHARMACEUTICAL, KWAI FA Pharmaceutical Group

What are the Application segmentation covered in the Mesalamine (Lialda) - Market report?

Ans: The Applications covered in the Mesalamine (Lialda) - Market report are Colitis, Crohn's Disease, Proctitis, Diarrheal Irritable Bowel Syndrome, Diverticulitis, Other

What are the Type segmentation covered in the Mesalamine (Lialda) - Market report?

Ans: The Types covered in the Mesalamine (Lialda) - Market report are Enemas, Tablets, Suppositories, Other

Recommended Reports

Inflammatory Bowel Drugs

Autoimmune & Arthritis

APIs & Drug Chemicals

1 Market Overview

1.1 Mesalamine (Lialda) Product Introduction

1.2 Global Mesalamine (Lialda) Market Size Forecast

1.3 Mesalamine (Lialda) Market Trends & Drivers

1.3.1 Mesalamine (Lialda) Industry Trends

1.3.2 Mesalamine (Lialda) Market Drivers & Opportunity

1.3.3 Mesalamine (Lialda) Market Challenges

1.3.4 Mesalamine (Lialda) Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Mesalamine (Lialda) Players Revenue Ranking (2023)

2.2 Global Mesalamine (Lialda) Revenue by Company (2019-2024)

2.3 Key Companies Mesalamine (Lialda) Manufacturing Base Distribution and Headquarters

2.4 Key Companies Mesalamine (Lialda) Product Offered

2.5 Key Companies Time to Begin Mass Production of Mesalamine (Lialda)

2.6 Mesalamine (Lialda) Market Competitive Analysis

2.6.1 Mesalamine (Lialda) Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Mesalamine (Lialda) Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mesalamine (Lialda) as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Enemas

3.1.2 Tablets

3.1.3 Suppositories

3.1.4 Other

3.2 Global Mesalamine (Lialda) Sales Value by Type

3.2.1 Global Mesalamine (Lialda) Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Mesalamine (Lialda) Sales Value, by Type (2019-2030)

3.2.3 Global Mesalamine (Lialda) Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Colitis

4.1.2 Crohn's Disease

4.1.3 Proctitis

4.1.4 Diarrheal Irritable Bowel Syndrome

4.1.5 Diverticulitis

4.1.6 Other

4.2 Global Mesalamine (Lialda) Sales Value by Application

4.2.1 Global Mesalamine (Lialda) Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Mesalamine (Lialda) Sales Value, by Application (2019-2030)

4.2.3 Global Mesalamine (Lialda) Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Mesalamine (Lialda) Sales Value by Region

5.1.1 Global Mesalamine (Lialda) Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Mesalamine (Lialda) Sales Value by Region (2019-2024)

5.1.3 Global Mesalamine (Lialda) Sales Value by Region (2025-2030)

5.1.4 Global Mesalamine (Lialda) Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Mesalamine (Lialda) Sales Value, 2019-2030

5.2.2 North America Mesalamine (Lialda) Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Mesalamine (Lialda) Sales Value, 2019-2030

5.3.2 Europe Mesalamine (Lialda) Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Mesalamine (Lialda) Sales Value, 2019-2030

5.4.2 Asia Pacific Mesalamine (Lialda) Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Mesalamine (Lialda) Sales Value, 2019-2030

5.5.2 South America Mesalamine (Lialda) Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Mesalamine (Lialda) Sales Value, 2019-2030

5.6.2 Middle East & Africa Mesalamine (Lialda) Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Mesalamine (Lialda) Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Mesalamine (Lialda) Sales Value

6.3 United States

6.3.1 United States Mesalamine (Lialda) Sales Value, 2019-2030

6.3.2 United States Mesalamine (Lialda) Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Mesalamine (Lialda) Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Mesalamine (Lialda) Sales Value, 2019-2030

6.4.2 Europe Mesalamine (Lialda) Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Mesalamine (Lialda) Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Mesalamine (Lialda) Sales Value, 2019-2030

6.5.2 China Mesalamine (Lialda) Sales Value by Type (%), 2023 VS 2030

6.5.3 China Mesalamine (Lialda) Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Mesalamine (Lialda) Sales Value, 2019-2030

6.6.2 Japan Mesalamine (Lialda) Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Mesalamine (Lialda) Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Mesalamine (Lialda) Sales Value, 2019-2030

6.7.2 South Korea Mesalamine (Lialda) Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Mesalamine (Lialda) Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Mesalamine (Lialda) Sales Value, 2019-2030

6.8.2 Southeast Asia Mesalamine (Lialda) Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Mesalamine (Lialda) Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Mesalamine (Lialda) Sales Value, 2019-2030

6.9.2 India Mesalamine (Lialda) Sales Value by Type (%), 2023 VS 2030

6.9.3 India Mesalamine (Lialda) Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Dr.Falk Pharma

7.1.1 Dr.Falk Pharma Profile

7.1.2 Dr.Falk Pharma Main Business

7.1.3 Dr.Falk Pharma Mesalamine (Lialda) Products, Services and Solutions

7.1.4 Dr.Falk Pharma Mesalamine (Lialda) Revenue (US$ Million) & (2019-2024)

7.1.5 Dr.Falk Pharma Recent Developments

7.2 Ferring

7.2.1 Ferring Profile

7.2.2 Ferring Main Business

7.2.3 Ferring Mesalamine (Lialda) Products, Services and Solutions

7.2.4 Ferring Mesalamine (Lialda) Revenue (US$ Million) & (2019-2024)

7.2.5 Ferring Recent Developments

7.3 Ethypharm Pharmaceutical

7.3.1 Ethypharm Pharmaceutical Profile

7.3.2 Ethypharm Pharmaceutical Main Business

7.3.3 Ethypharm Pharmaceutical Mesalamine (Lialda) Products, Services and Solutions

7.3.4 Ethypharm Pharmaceutical Mesalamine (Lialda) Revenue (US$ Million) & (2019-2024)

7.3.5 Shanghai Pharmaceutical Recent Developments

7.4 Shanghai Pharmaceutical

7.4.1 Shanghai Pharmaceutical Profile

7.4.2 Shanghai Pharmaceutical Main Business

7.4.3 Shanghai Pharmaceutical Mesalamine (Lialda) Products, Services and Solutions

7.4.4 Shanghai Pharmaceutical Mesalamine (Lialda) Revenue (US$ Million) & (2019-2024)

7.4.5 Shanghai Pharmaceutical Recent Developments

7.5 Tillotts Pharma

7.5.1 Tillotts Pharma Profile

7.5.2 Tillotts Pharma Main Business

7.5.3 Tillotts Pharma Mesalamine (Lialda) Products, Services and Solutions

7.5.4 Tillotts Pharma Mesalamine (Lialda) Revenue (US$ Million) & (2019-2024)

7.5.5 Tillotts Pharma Recent Developments

7.6 Holy Stone Healthcare

7.6.1 Holy Stone Healthcare Profile

7.6.2 Holy Stone Healthcare Main Business

7.6.3 Holy Stone Healthcare Mesalamine (Lialda) Products, Services and Solutions

7.6.4 Holy Stone Healthcare Mesalamine (Lialda) Revenue (US$ Million) & (2019-2024)

7.6.5 Holy Stone Healthcare Recent Developments

7.7 Giuliani

7.7.1 Giuliani Profile

7.7.2 Giuliani Main Business

7.7.3 Giuliani Mesalamine (Lialda) Products, Services and Solutions

7.7.4 Giuliani Mesalamine (Lialda) Revenue (US$ Million) & (2019-2024)

7.7.5 Giuliani Recent Developments

7.8 Zeria

7.8.1 Zeria Profile

7.8.2 Zeria Main Business

7.8.3 Zeria Mesalamine (Lialda) Products, Services and Solutions

7.8.4 Zeria Mesalamine (Lialda) Revenue (US$ Million) & (2019-2024)

7.8.5 Zeria Recent Developments

7.9 Lupin

7.9.1 Lupin Profile

7.9.2 Lupin Main Business

7.9.3 Lupin Mesalamine (Lialda) Products, Services and Solutions

7.9.4 Lupin Mesalamine (Lialda) Revenue (US$ Million) & (2019-2024)

7.9.5 Lupin Recent Developments

7.10 Heilongjiang Tianhong Pharmaceutical

7.10.1 Heilongjiang Tianhong Pharmaceutical Profile

7.10.2 Heilongjiang Tianhong Pharmaceutical Main Business

7.10.3 Heilongjiang Tianhong Pharmaceutical Mesalamine (Lialda) Products, Services and Solutions

7.10.4 Heilongjiang Tianhong Pharmaceutical Mesalamine (Lialda) Revenue (US$ Million) & (2019-2024)

7.10.5 Heilongjiang Tianhong Pharmaceutical Recent Developments

7.11 HENGCHENG PHARMACEUTICAL

7.11.1 HENGCHENG PHARMACEUTICAL Profile

7.11.2 HENGCHENG PHARMACEUTICAL Main Business

7.11.3 HENGCHENG PHARMACEUTICAL Mesalamine (Lialda) Products, Services and Solutions

7.11.4 HENGCHENG PHARMACEUTICAL Mesalamine (Lialda) Revenue (US$ Million) & (2019-2024)

7.11.5 HENGCHENG PHARMACEUTICAL Recent Developments

7.12 KWAI FA Pharmaceutical Group

7.12.1 KWAI FA Pharmaceutical Group Profile

7.12.2 KWAI FA Pharmaceutical Group Main Business

7.12.3 KWAI FA Pharmaceutical Group Mesalamine (Lialda) Products, Services and Solutions

7.12.4 KWAI FA Pharmaceutical Group Mesalamine (Lialda) Revenue (US$ Million) & (2019-2024)

7.12.5 KWAI FA Pharmaceutical Group Recent Developments

8 Industry Chain Analysis

8.1 Mesalamine (Lialda) Industrial Chain

8.2 Mesalamine (Lialda) Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Mesalamine (Lialda) Sales Model

8.5.2 Sales Channel

8.5.3 Mesalamine (Lialda) Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Dr. Falk Pharma

Ferring

Ethypharm Pharmaceutical

Shanghai Pharmaceutical

Tillotts Pharma

Holy Stone Healthcare

GIULIANI

Zeria

Lupin Ltd

Heilongjiang Tianhong Pharmaceutical

Hengcheng Pharmaceutical

KWAI FA Pharmaceutical Group

List of Tables

Table 1. Mesalamine (Lialda) Market Trends

Table 2. Mesalamine (Lialda) Market Drivers & Opportunity

Table 3. Mesalamine (Lialda) Market Challenges

Table 4. Mesalamine (Lialda) Market Restraints

Table 5. Global Mesalamine (Lialda) Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Mesalamine (Lialda) Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Mesalamine (Lialda) Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Mesalamine (Lialda) Product Type

Table 9. Key Companies Time to Begin Mass Production of Mesalamine (Lialda)

Table 10. Global Mesalamine (Lialda) Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mesalamine (Lialda) as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Mesalamine (Lialda) Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Mesalamine (Lialda) Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Mesalamine (Lialda) Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Mesalamine (Lialda) Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Mesalamine (Lialda) Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Mesalamine (Lialda) Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Mesalamine (Lialda) Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Mesalamine (Lialda) Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Mesalamine (Lialda) Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Mesalamine (Lialda) Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Mesalamine (Lialda) Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Mesalamine (Lialda) Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Mesalamine (Lialda) Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Mesalamine (Lialda) Sales Value by Region (2019-2024) & (%)

Table 27. Global Mesalamine (Lialda) Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Mesalamine (Lialda) Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Mesalamine (Lialda) Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Mesalamine (Lialda) Sales Value, (2025-2030) & (US$ Million)

Table 31. Dr.Falk Pharma Basic Information List

Table 32. Dr.Falk Pharma Description and Business Overview

Table 33. Dr.Falk Pharma Mesalamine (Lialda) Products, Services and Solutions

Table 34. Revenue (US$ Million) in Mesalamine (Lialda) Business of Dr.Falk Pharma (2019-2024)

Table 35. Dr.Falk Pharma Recent Developments

Table 36. Ferring Basic Information List

Table 37. Ferring Description and Business Overview

Table 38. Ferring Mesalamine (Lialda) Products, Services and Solutions

Table 39. Revenue (US$ Million) in Mesalamine (Lialda) Business of Ferring (2019-2024)

Table 40. Ferring Recent Developments

Table 41. Ethypharm Pharmaceutical Basic Information List

Table 42. Ethypharm Pharmaceutical Description and Business Overview

Table 43. Ethypharm Pharmaceutical Mesalamine (Lialda) Products, Services and Solutions

Table 44. Revenue (US$ Million) in Mesalamine (Lialda) Business of Ethypharm Pharmaceutical (2019-2024)

Table 45. Ethypharm Pharmaceutical Recent Developments

Table 46. Shanghai Pharmaceutical Basic Information List

Table 47. Shanghai Pharmaceutical Description and Business Overview

Table 48. Shanghai Pharmaceutical Mesalamine (Lialda) Products, Services and Solutions

Table 49. Revenue (US$ Million) in Mesalamine (Lialda) Business of Shanghai Pharmaceutical (2019-2024)

Table 50. Shanghai Pharmaceutical Recent Developments

Table 51. Tillotts Pharma Basic Information List

Table 52. Tillotts Pharma Description and Business Overview

Table 53. Tillotts Pharma Mesalamine (Lialda) Products, Services and Solutions

Table 54. Revenue (US$ Million) in Mesalamine (Lialda) Business of Tillotts Pharma (2019-2024)

Table 55. Tillotts Pharma Recent Developments

Table 56. Holy Stone Healthcare Basic Information List

Table 57. Holy Stone Healthcare Description and Business Overview

Table 58. Holy Stone Healthcare Mesalamine (Lialda) Products, Services and Solutions

Table 59. Revenue (US$ Million) in Mesalamine (Lialda) Business of Holy Stone Healthcare (2019-2024)

Table 60. Holy Stone Healthcare Recent Developments

Table 61. Giuliani Basic Information List

Table 62. Giuliani Description and Business Overview

Table 63. Giuliani Mesalamine (Lialda) Products, Services and Solutions

Table 64. Revenue (US$ Million) in Mesalamine (Lialda) Business of Giuliani (2019-2024)

Table 65. Giuliani Recent Developments

Table 66. Zeria Basic Information List

Table 67. Zeria Description and Business Overview

Table 68. Zeria Mesalamine (Lialda) Products, Services and Solutions

Table 69. Revenue (US$ Million) in Mesalamine (Lialda) Business of Zeria (2019-2024)

Table 70. Zeria Recent Developments

Table 71. Lupin Basic Information List

Table 72. Lupin Description and Business Overview

Table 73. Lupin Mesalamine (Lialda) Products, Services and Solutions

Table 74. Revenue (US$ Million) in Mesalamine (Lialda) Business of Lupin (2019-2024)

Table 75. Lupin Recent Developments

Table 76. Heilongjiang Tianhong Pharmaceutical Basic Information List

Table 77. Heilongjiang Tianhong Pharmaceutical Description and Business Overview

Table 78. Heilongjiang Tianhong Pharmaceutical Mesalamine (Lialda) Products, Services and Solutions

Table 79. Revenue (US$ Million) in Mesalamine (Lialda) Business of Heilongjiang Tianhong Pharmaceutical (2019-2024)

Table 80. Heilongjiang Tianhong Pharmaceutical Recent Developments

Table 81. HENGCHENG PHARMACEUTICAL Basic Information List

Table 82. HENGCHENG PHARMACEUTICAL Description and Business Overview

Table 83. HENGCHENG PHARMACEUTICAL Mesalamine (Lialda) Products, Services and Solutions

Table 84. Revenue (US$ Million) in Mesalamine (Lialda) Business of HENGCHENG PHARMACEUTICAL (2019-2024)

Table 85. HENGCHENG PHARMACEUTICAL Recent Developments

Table 86. KWAI FA Pharmaceutical Group Basic Information List

Table 87. KWAI FA Pharmaceutical Group Description and Business Overview

Table 88. KWAI FA Pharmaceutical Group Mesalamine (Lialda) Products, Services and Solutions

Table 89. Revenue (US$ Million) in Mesalamine (Lialda) Business of KWAI FA Pharmaceutical Group (2019-2024)

Table 90. KWAI FA Pharmaceutical Group Recent Developments

Table 91. Key Raw Materials Lists

Table 92. Raw Materials Key Suppliers Lists

Table 93. Mesalamine (Lialda) Downstream Customers

Table 94. Mesalamine (Lialda) Distributors List

Table 95. Research Programs/Design for This Report

Table 96. Key Data Information from Secondary Sources

Table 97. Key Data Information from Primary Sources

Table 98. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Mesalamine (Lialda) Product Picture

Figure 2. Global Mesalamine (Lialda) Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Mesalamine (Lialda) Sales Value (2019-2030) & (US$ Million)

Figure 4. Mesalamine (Lialda) Report Years Considered

Figure 5. Global Mesalamine (Lialda) Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Mesalamine (Lialda) Revenue in 2023

Figure 7. Mesalamine (Lialda) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Enemas Picture

Figure 9. Tablets Picture

Figure 10. Suppositories Picture

Figure 11. Other Picture

Figure 12. Global Mesalamine (Lialda) Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 13. Global Mesalamine (Lialda) Sales Value Market Share by Type, 2023 & 2030

Figure 14. Product Picture of Colitis

Figure 15. Product Picture of Crohn's Disease

Figure 16. Product Picture of Proctitis

Figure 17. Product Picture of Diarrheal Irritable Bowel Syndrome

Figure 18. Product Picture of Diverticulitis

Figure 19. Product Picture of Other

Figure 20. Global Mesalamine (Lialda) Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 21. Global Mesalamine (Lialda) Sales Value Market Share by Application, 2023 & 2030

Figure 22. North America Mesalamine (Lialda) Sales Value (2019-2030) & (US$ Million)

Figure 23. North America Mesalamine (Lialda) Sales Value by Country (%), 2023 VS 2030

Figure 24. Europe Mesalamine (Lialda) Sales Value (2019-2030) & (US$ Million)

Figure 25. Europe Mesalamine (Lialda) Sales Value by Country (%), 2023 VS 2030

Figure 26. Asia Pacific Mesalamine (Lialda) Sales Value (2019-2030) & (US$ Million)

Figure 27. Asia Pacific Mesalamine (Lialda) Sales Value by Country (%), 2023 VS 2030

Figure 28. South America Mesalamine (Lialda) Sales Value (2019-2030) & (US$ Million)

Figure 29. South America Mesalamine (Lialda) Sales Value by Country (%), 2023 VS 2030

Figure 30. Middle East & Africa Mesalamine (Lialda) Sales Value (2019-2030) & (US$ Million)

Figure 31. Middle East & Africa Mesalamine (Lialda) Sales Value by Country (%), 2023 VS 2030

Figure 32. Key Countries/Regions Mesalamine (Lialda) Sales Value (%), (2019-2030)

Figure 33. United States Mesalamine (Lialda) Sales Value, (2019-2030) & (US$ Million)

Figure 34. United States Mesalamine (Lialda) Sales Value by Type (%), 2023 VS 2030

Figure 35. United States Mesalamine (Lialda) Sales Value by Application (%), 2023 VS 2030

Figure 36. Europe Mesalamine (Lialda) Sales Value, (2019-2030) & (US$ Million)

Figure 37. Europe Mesalamine (Lialda) Sales Value by Type (%), 2023 VS 2030

Figure 38. Europe Mesalamine (Lialda) Sales Value by Application (%), 2023 VS 2030

Figure 39. China Mesalamine (Lialda) Sales Value, (2019-2030) & (US$ Million)

Figure 40. China Mesalamine (Lialda) Sales Value by Type (%), 2023 VS 2030

Figure 41. China Mesalamine (Lialda) Sales Value by Application (%), 2023 VS 2030

Figure 42. Japan Mesalamine (Lialda) Sales Value, (2019-2030) & (US$ Million)

Figure 43. Japan Mesalamine (Lialda) Sales Value by Type (%), 2023 VS 2030

Figure 44. Japan Mesalamine (Lialda) Sales Value by Application (%), 2023 VS 2030

Figure 45. South Korea Mesalamine (Lialda) Sales Value, (2019-2030) & (US$ Million)

Figure 46. South Korea Mesalamine (Lialda) Sales Value by Type (%), 2023 VS 2030

Figure 47. South Korea Mesalamine (Lialda) Sales Value by Application (%), 2023 VS 2030

Figure 48. Southeast Asia Mesalamine (Lialda) Sales Value, (2019-2030) & (US$ Million)

Figure 49. Southeast Asia Mesalamine (Lialda) Sales Value by Type (%), 2023 VS 2030

Figure 50. Southeast Asia Mesalamine (Lialda) Sales Value by Application (%), 2023 VS 2030

Figure 51. India Mesalamine (Lialda) Sales Value, (2019-2030) & (US$ Million)

Figure 52. India Mesalamine (Lialda) Sales Value by Type (%), 2023 VS 2030

Figure 53. India Mesalamine (Lialda) Sales Value by Application (%), 2023 VS 2030

Figure 54. Mesalamine (Lialda) Industrial Chain

Figure 55. Mesalamine (Lialda) Manufacturing Cost Structure

Figure 56. Channels of Distribution (Direct Sales, and Distribution)

Figure 57. Bottom-up and Top-down Approaches for This Report

Figure 58. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Mesalazine Market Research Report 2024

Global Mesalazine API Market Research Report 2025

Global Mesalamine Market Research Report 2024

Global Mesalazine Suppositories Market Research Report 2024

Global Mesalamine API Market Research Report 2024

Rectal Mesalazine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Drug for Ulcerative Colitis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Ulcerative Colitis Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Ulcerative Colitis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Balsalazide Disodium Market Research Report 2025

5 aminosalicylic Acid API Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Aminosalicylic Acid Preparation Market Insights Forecast to 2030

Budesonide Capsules Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Adalimumab Market Insights Forecast to 2030

Anti inflammatory Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Salicylsalicylic Acid Market Research Report 2024

Global Mesalazine Enteric Coated Tablets Market Research Report 2024

Inflammatory Bowel Disease IBD Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Humira Market Insights Forecast to 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions